The late-stage biopharmaceutical company, IntraBio Inc. shared exciting news about the approval of the Extension Phase for the IB1001-201 Clinical Trial in all those countries across Europe where they’re conducting the trial.
Various centers across Europe, such as the U.K, Spain, Germany, and Slovakia are conducting the IB1001-201 trial which investigates N-acetyl-L-leucine (IB1001) for the Niemann-Pick disease Type C (NPC) treatment.
The treatment of the patients with IB1001 who are already undergoing the trial will be continued now that Extension Phase has been approved. This is, however, if it is determined by the principal investigator that the continuation is in the best interest of the patient.
The aim of the Extension Phase is to determine how effective the trial has been and gather more evidence of IB1001’s symptomatic benefit. The in vivo and in vitro data strongly support the Acetyl Leucine’s long-term benefit.
Pediatric patients are predominantly affected by NPC, an uncommon, debilitating, lysosomal storage disorder and are inherited. The disease affects children at an early age and is a long term disease that keeps progressing constantly. The life quality of a child can get severely affected by this disease. On average, children suffering from NPC die when they reach the age of 10.
New treatments for usual and unusual neurodegenerative diseases are being offered at IntraBio Inc., a U.S. biopharmaceutical company. Years and years of research and investment has been put at the leading world universities and institutions in order to give birth to this biopharmaceutical company. The scientific founders of the company are from the University of Oxford and the University of Munich and this can be seen in the expertise that is leveraged in the clinical programs offered by the company in intracellular calcium signaling and lysosomal function.
The US Corporation of IntraBio has its major laborites and offices placed in Oxford, U.K.